SCHEMBL3022485

SCHEMBL3022485

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)CC3)n2)cc(OC)c1OC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 5/20 0.40
MAPK1 P28482 3/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
PKM P14618 2/20 0.36
F2RL3 Q96RI0 3/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
AR P10275 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006307 0.90 MAPT (0.45) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL2999939 0.90 HSD17B10 (0.42) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3007995 0.88 MAPT (0.46) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL2997927 0.88 HTR6 (0.39) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3021156 0.88 ALDH1A1 (0.42) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3007798 0.88 MEN1 (0.40) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3007158 0.87 MAPT (0.56) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3019251 0.85 ALDH1A1 (0.38) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3011410 0.85 ALDH1A1 (0.40) USP2MAPTRECQLHSD17B10ALDH1A1
SCHEMBL3004144 0.85 ALDH1A1 (0.39) MAPTALDH1A1MAPK1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA USP2 1831/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.